Elisa assay for detecting antibodies against blv surface antigen gp 51 in bovine serum

ABSTRACT

The subject of the present invention is a method of obtaining purified BLV gp 51  antigen as well as a novel ELISA assay using said antigen. The present invention is useful in the diagnosis of enzootic leukaemia in cattle.

The subject of the present invention is a method of obtaining purified BLV gp51 antigen as well as a novel ELISA assay using said antigen. The present invention is useful in the diagnosis of enzootic leukaemia in cattle.

Enzootic bovine leukaemia (EBL) is an infectious disease of cattle caused by a type C retrovirus, BLV (Bovine Leukaemia Virus) and consists of lymphatic node hypertrophy. The disease is characterised by a long incubation period (up to 7 years) and, in most cases, (ca. 60%) proceeds without symptoms. Lymphatic cysts form in a portion of adult cattle (10-30%), whereas 1-10% develop lymphatic sarcomas on various internal organs, with a marked increase of B lymphocytes.

A strong immune response occurs in infected individuals, which is used in serological diagnostics. Despite the fact that the titre of anti-BLV antibodies increases as the disease progresses, they are not able to halt the infection. Because the disease develops asymptomatically through a long initial phase, the only effective method of preventing transmission are frequent serological diagnostics and the elimination of infected animals. Serological assays are performed on animals over 6 months, when maternal antibodies have begun disappearing. The virus itself can be detected in isolated peripheral lymphocytes using an electron microscope, and viral DNA can be diagnosed using PCR. Immunological assays are used most frequently to diagnose bovine leukaemia: gel immunodiffusion (AGID), immunoenzymatic assays (ELISA) as well as radioimmunological detection. These methods make use of antibodies against the antigenic proteins gp51 and p24.

ELISA assays for diagnosing enzootic bovine leukaemia are based on the determination of anti-BLV antibody levels in serum or milk. To construct the assay kit it is necessary to produce purified gp51 viral surface antigen. This antigen is produced in a culture of FLK cells infected with BLV. Cell cultures make frequent use of calf serum (FCS) containing bovine immunoglobulins that, despite tedious purification procedures, contaminate the resulting preparations with bovine antibodies, which leads to false positive results.

Available literature describes a series of labour-intensive methods of purifying the gp51 antigen, encompassing precipitation, extraction, centrifugation in a saccharose gradient, gel and ion exchange chromatography (Grunboeck M. et al., Polskie Archiwum Weterynaryjne 1986, 24, 327-336). Ukrainian patent (UA 68930 A) describes a culture medium containing avian serum (instead of bovine). The production of the purified antigen, however, requires the removal of a large quantity of ballasting avian antigens.

The unsolved problem in prior art are the difficult, tedious and expensive methods of purifying the antigen to be used in the ELISA assay. At the same time, due to the problems at this stage, contaminated antigen preparations are produced, which, when used in an ELISA assay, lead to erroneous results and make rapid and effective diagnostics of the disease impossible.

The subject of the present invention is a method of obtaining pure BLV gp51 antigen characterised in that the antigen production process uses culture media totally devoid of bovine serum.

In a preferential embodiment of the present invention, culture media for FLK-BLV cells are used.

In the next preferential embodiment of the present invention, the culture media encompass HyQ SFM4MegaVir, HyQ PF-Vero, and Gibco Opti Pro SFM.

The next subject of the present invention is the use of purified BLV gp51 antigen in a gel immunodiffusion assay or an ELISA assay.

The next subject of the present invention is a novel ELISA assay for detecting enzootic leukaemia in cattle, characterised in that it contains a highly pure BLV gp51 BLV antigen obtained from cell culture media totally devoid of bovine serum.

An example embodiment of the present invention, which does not exhaust the scope of its protection, is given below.

EXAMPLE

FLK-BLV cells are cultured in dishes or culture flasks in DMEM medium without bovine serum, for example HyQ SFM4MegaVir, HyQ PF-Vero and Gibco Opti Pro SFM. The culture is maintained for 2-3 days until the cells reach a large density, and then for the subsequent several days, the medium is collected from above the cells and is maintained at −20° C. The collected medium is condensed 10-fold via ultrafiltration using an Amicon YM10 membrane and dialysed against 20 mM Tris-HCl pH 7.5, whereafter it is purified in a DEAE-Sepharose FF column equilibrated with 20 mM Tris-HCl pH 7.5 and eluted with a sodium chloride gradient (0-500 mM). Antigen gp51-containing fractions are pooled, dialysed against PBS and stored at −20 C.

The antigen thus obtained can be used in gel immunodiffusion assays or ELISA assays. 

1. A method of producing purified BLV gp51 antigen, characterised in that the antigen production process uses cell culture media totally devoid of bovine serum.
 2. A method according to claim 1, characterised in that culture media for FLK-BLV cells are used.
 3. A method according to claim 1, characterised in that the culture media encompass HyQ SFM4MegaVir, HyQ PF-Vero and Gibco Opti Pro SFM.
 4. The use of purified BLV gp51 antigen according to claim 1 in an immunodiffusion assay or ELISA assay.
 5. A novel ELISA assay for detecting enzootic leukaemia in cattle, characterised in that it contains a highly purified BLV gp51 antigen obtained from cell culture media entirely devoid of bovine serum. 